<DOC>
	<DOCNO>NCT01684982</DOCNO>
	<brief_summary>Randomized trial test efficacy safety new Drug Eluting Stent generation patient acute myocardial infarction treat primary percutaneous coronary intervention ( PCI )</brief_summary>
	<brief_title>Everolimus Stent Myocardial Infarction</brief_title>
	<detailed_description>The efficacy safety drug-eluting stent ( DES ) treatment coronary artery disease well establish . It well know Drug Eluting Stent ( DES ) dramatically decrease Restenosis rate on-label off-label indication . However , concern increase ( late ) stent thrombosis still present DES implantation patient acute myocardial infarction still controversial acute coronary lesion present high possible thrombotic burden Newer DES new antiproliferative drug biocompatible polymer show significant reduction ( late ) stent thrombosis patient stable condition . Aim study ass long term efficacy safety second generation everolimus elute stent compare first generation sirolimus elute stent</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>All ST segment elevation myocardial infarction ( STEMI ) patient eligible primary PCI 1 . Contraindication dual antiplatelet therapy 12 month 2 . Known allergy sirolimus everolimus 3 . Major surgical procedure plan within 1 month . 4 . History , symptom , finding suggestive aortic dissection . 5 . Participation trial 6 . Pregnancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>April 2013</verification_date>
	<keyword>Primary PCI</keyword>
	<keyword>Drug Eluting Stent</keyword>
</DOC>